Details for: AVONEX
Company: BIOGEN CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02269201 | AVONEX | INTERFERON BETA-1A | 30 MCG / 0.5 ML | SOLUTION | INTRAMUSCULAR |
Summary Reports
Summary Safety Review - AVONEX (interferon beta-1a) - Assessing the Potential Risk of Kidney Damage (nephrotic syndrome)
Summary Safety Review - Interferon beta products - Assessing the Potential Risk of Pulmonary Arterial Hypertension
Summary Safety Review - AVONEX (interferon beta-1a) - Assessing the Potential Risk of Kidney Damage (nephrotic syndrome)
Summary Safety Review - Interferon-beta Products - Thrombotic Microangiopathy
Summary Safety Review - AVONEX (interferon beta-1a) - Assessing the Potential Risk of an Inflammatory Disease that Affects One or More Organs (Sarcoidosis)
Summary Safety Review - Interferon beta products - Assessing the Potential Risk of Pulmonary Arterial Hypertension
Summary Safety Review - AVONEX (interferon beta-1a) - Assessing the Potential Risk of Kidney Damage (nephrotic syndrome)
Summary Safety Review - Interferon-beta Products - Thrombotic Microangiopathy
Summary Safety Review - AVONEX (interferon beta-1a) - Assessing the Potential Risk of an Inflammatory Disease that Affects One or More Organs (Sarcoidosis)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.